1. Home
  2. NIE vs ARVN Comparison

NIE vs ARVN Comparison

Compare NIE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$26.88

Market Cap

745.4M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.94

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIE
ARVN
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.4M
658.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NIE
ARVN
Price
$26.88
$8.94
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$15.05
AVG Volume (30 Days)
64.8K
858.9K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
9.04%
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.74
$6.06
52 Week High
$27.02
$14.22

Technical Indicators

Market Signals
Indicator
NIE
ARVN
Relative Strength Index (RSI) 65.39 37.05
Support Level $24.71 $8.72
Resistance Level $27.02 $10.18
Average True Range (ATR) 0.32 0.47
MACD -0.03 0.00
Stochastic Oscillator 91.92 28.82

Price Performance

Historical Comparison
NIE
ARVN

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: